Evidence map›Paper›PMID 20570586›Full record

ArticleChemico-biological interactions2010

1-Benzyl-indole-3-carbinol is a novel indole-3-carbinol derivative with significantly enhanced potency of anti-proliferative and anti-estrogenic properties in human breast cancer cells.

Hanh H Nguyen, Sergey N Lavrenov, Shyam N Sundar, David H H Nguyen, Min Tseng, Crystal N Marconett, Jenny Kung, Richard E Staub, Maria N Preobrazhenskaya, Leonard F Bjeldanes and 1 more

Abstract read
In one paragraph

Article in Chemico-biological interactions, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Genotoxicity Studies of Indole-3-carbinol andPharmaceuticals (Basel, Switzerland) · 2026
    Article
  3. Design, synthesis,RSC medicinal chemistry · 2024
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Phytochemicals for the Management of Melanoma.Mini reviews in medicinal chemistry · 2016
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Hanh H NguyenDepartment of Molecular and Cell Biology and The Cancer Research Laboratory, Univ. of California at Berkeley, Berkeley, CA 94720-3200, United States.
Sergey N Lavrenov
Shyam N Sundar
David H H Nguyen
Min Tseng
Crystal N Marconett
Jenny Kung
Richard E Staub
Maria N Preobrazhenskaya
Leonard F Bjeldanes
Gary L Firestone
University of California, Berkeley · USGause Institute of New Antibiotics Russian Academy of Medical Sciences · RU

Funding

Transcriptional &cell cycle control by dietary indolesR01CA102360 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI FIRESTONE, GARY L · 2004 to 2008
$1.3M
NCI NIH HHS CA102360NCI NIH HHS R01 CA102360
6 · The paper itself

Abstract

Indole-3-carbinol (I3C), a natural autolysis product of a gluccosinolate present in Brassica vegetables such as broccoli and cabbage, has anti-proliferative and anti-estrogenic activities in human breast cancer cells. A new and significantly more potent I3C analogue, 1-benzyl-I3C was synthesized, and in comparison to I3C, this novel derivative displayed an approximate 1000-fold enhanced potency in suppressing the growth of both estrogen responsive (MCF-7) and estrogen-independent (MDA-MB-231) human breast cancer cells (I3C IC(50) of 52 microM, and 1-benzyl-I3C IC(50) of 0.05 microM). At significantly lower concentrations, 1-benzyl-I3C induced a robust G1 cell cycle arrest and elicited the key I3C-specific effects on expression and activity of G1-acting cell cycle genes including the disruption of endogenous interactions of the Sp1 transcription factor with the CDK6 promoter. Furthermore, in estrogen responsive MCF-7 cells, with enhanced potency 1-benzyl-I3C down-regulated production of estrogen receptor-alpha protein, acts with tamoxifen to arrest breast cancer cell growth more effectively than either compound alone, and inhibited the in vivo growth of human breast cancer cell-derived tumor xenografts in athymic mice. Our results implicate 1-benzyl-I3C as a novel, potent inhibitor of human breast cancer proliferation and estrogen responsiveness that could potentially be developed into a promising therapeutic agent for the treatment of indole-sensitive cancers.

Indexed as

AnimalsAnticarcinogenic AgentsBenzyl CompoundsBrassicaBreast NeoplasmsCell CycleCell Line, TumorCell ProliferationCyclin-Dependent Kinase 6DNAEstrogen AntagonistsEstrogen Receptor alphaFemaleGene Expression Regulation, NeoplasticHumansIndolesAnticarcinogenic AgentsBenzyl CompoundsCyclin-Dependent Kinase 6DNAEstrogen AntagonistsEstrogen Receptor alphaindole-3-carbinolIndolesSp1 Transcription Factor

Identifiers

PMID20570586
PMCPMC3422669
OpenAlexW2161185865

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.